Abstract
We report our preliminary results of a pilot clinical trial of late-stage breast cancer patients treated by laser immunotherapy (LIT), a local intervention using an 805 nm laser for non-invasive irradiation, indocyanine green for selective thermal effect, and immunoadjuvant (glycated chitosan) for immunological stimulation. Ten breast cancer patients were enrolled in this study; all patients were considered to be out of other available treatment options. Toxicity was individually evaluated through physical exams and laboratory tests. Adverse reactions only occurred in the area of treatment due to photothermal injury and local administration of immunoadjuvant. No grade 3 or 4 side effects were observed. Treatment efficacy of LIT was also evaluated by physical examination and tomography. In 8 patients available for evaluation, the objective response rate was 62.5% and the clinical beneficial response rate was 75%. While the study is still ongoing, the initial outcomes of this clinical trial show that LIT is well tolerated and is promising in the treatment of metastatic breast cancer.
Similar content being viewed by others
References
O. J. Finn, N. Engl. J. Med., 2008, 358, 2704–2715.
T. A. Waldmann, Nat. Med., 2003, 9, 269–277.
J. W. Simons, M. A. Carducci, B. Mikhak, M. Lim, B. Biedrzycki, F. Borellini, S. M. Clift, K. M. Hege, D. G. Ando, S. Piantadosi, R. Mulligan and W. G. Nelson, Clin. Cancer Res., 2006, 12, 3394–3401.
E. J. Small, N. Sacks, J. Nemunaitis, W. J. Urba, E. Dula, A. S. Centeno, W. G. Nelson, D. Ando, C. Howard, F. Borellini, M. Nguyen, K. Hege and J. W. Simons, Clin. Cancer Res., 2007, 13, 3883–3891.
I. Komenaka, H. Hoerig and L. Kaufman, Clin. Dermatol., 2004, 22, 251–265.
W. R. Chen, R. L. Adams, R. Carubelli and R. E. Nordquist, Cancer Lett., 1997, 115, 25–30.
W. R. Chen, R. Carubelli, H. Liu and R. E. Nordquist, Mol. Biotechnol., 2003, 25, 37–43.
W. R. Chen, H. Liu, J. W. Ritchey, K. E. Bartels, M. D. Lucroy and R. E. Nordquist, Cancer Res., 2002, 62, 4295–4299.
S. Song, F. Zhou, R. E. Nordquist, R. Carubelli, H. Liu and W. R. Chen, Immunopharmacol. Immunotoxicol., 2009, 31, 202–208.
W. R. Chen, S. W. Jeong, M. D. Lucroy, R. F. Wolf, E. W. Howard, H. Liu and R. E. Nordquist, Int. J. Cancer, 2003, 107, 1053–1057.
W. R. Chen, W. G. Zhu, J. R. Dynlacht, H. Liu and R. E. Nordquist, Int. J. Cancer, 1999, 81, 808–812.
W. R. Chen, A. K. Singhal, H. Liu and R. E. Nordquist, Cancer Res., 2001, 61, 459–461.
S. E. Singletary and J. L. Connolly, Ca-Cancer J. Clin., 2006, 56, 37–47.
US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis: Common terminology criteria for adverse events v3.0 (CTCAE). Available: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf [accessed September 28, 2009].
J. D. Wolchok, A. Hoos, S. O’Day, J. S. Weber, O. Hamid, C. Lebbé, M. Maio, M. Binder, O. Bohnsack, G. Nichol, R. Humphrey and F. S. Hodi, Clin. Cancer Res., 2009, 15, 7412–7420.
S. Martin, M. Mannino, A. Rostom, D. Tait, E. Donovan, S. Eagle, J. Haviland and J. Yarnold, Clin. Oncol. (R. Coll. Radiol.), 2008, 20, 502–505.
R. Keskikuru, A. Jukkola, J. Nuutinen, V. Kataja, J. Risteli, P. Autio and T. Lahtinen, Radiother. Oncol., 2004, 70, 243–248.
G. Viale and L. Bottiglieri, Eur. J. Cancer, 2009, 45(Suppl 1), 5–10.
S. Y. Jung, H. Y. Kim, B. H. Nam, S. Y. Min, S. J. Lee, C. Park, Y. Kwon, E. A. Kim, K. L. Ko, K. H. Shin, K. S. Lee, I. H. Park, S. Lee, S. W. Kim, H. S. Kang and J. Ro, Breast Cancer Res. Treat., 2010, 120, 627–637.
E. A. Perez, A. Moreno-Aspitia, E. Aubrey Thompson and C. A. Andorfer, Breast Cancer Res. Treat., 2010, 120, 285–291.
E. Jäger, D. Jäger and A. Knuth, Int. J. Cancer, 2003, 106, 817–820.
M. H. den Brok, R. P. Sutmuller, R. Van Der Voort, E. J. Bennink, C. G. Figdor, T. J. Ruers and G. J. Adema, Cancer Res., 2004, 64, 4024–4029.
H. G. Zhang, K. Mehta, P. Cohen and C. Guha, Cancer Lett., 2008, 271, 191–204.
V. Milani and E. Noessner, Cancer Immunol. Immunother., 2005, 55, 312–319.
S. Koido, E. Hara, S. Homma, K. Fujise, J. Gong and H. Tajiri, Arch. Immunol. Ther. Exp., 2007, 55, 281–287.
A. Mukhopadhaya, J. Mendecki, X. Dong, L. Liu, S. Kalnicki, M. Garg, A. Alfieri and C. Guha, Cancer Res., 2007, 67, 7798–7806.
J. Guo, J. Zhu, X. Sheng, X. Wang, L. Qu, Y. Han, Y. Liu, H. Zhang, L. Huo, S. Zhang, B. Lin and Z. Yang, Int. J. Cancer, 2007, 120, 2418–2425.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published as part of a themed issue on immunological aspects and drug delivery technologies in PDT.
Rights and permissions
About this article
Cite this article
Li, X., Ferrel, G.L., Guerra, M.C. et al. Preliminary safety and efficacy results of laser immunotherapy for the treatment of metastatic breast cancer patients. Photochem Photobiol Sci 10, 817–821 (2011). https://doi.org/10.1039/c0pp00306a
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1039/c0pp00306a